Latest Breaking News On - பரப்பளவு கீழ் - Page 8 : comparemela.com
Israel nimmt Hamas-Führer ins Visier
sat1.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sat1.de Daily Mail and Mail on Sunday newspapers.
Dự Báo Thời Tiết Ngày 13/5/2021: Vùng Núi Phía Bắc, Trung Trung Bộ Nắng Trên Diện Rộng
tin247.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tin247.com Daily Mail and Mail on Sunday newspapers.
Dự báo thời tiết ngày13/5/2021: Nắng nóng trên diện rộng
nguoiduatin.vn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nguoiduatin.vn Daily Mail and Mail on Sunday newspapers.
Lexaria Bioscience Corp.: Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1
Up to 1,737% more CBD delivered into brain tissue
KELOWNA, BC / ACCESSWIRE / May 6, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the Company or Lexaria ), a global innovator in drug delivery platforms, is pleased to announce successful outcomes in its first sets of data from its 2021 applied research and development (R&D) study programs.
Study HYPER-A21-1 included three new DehydraTECH 2.0 formulation variations designed to enable cannabidiol ( CBD ) delivery performance enhancements and pharmacokinetic optimization. All three new DehydraTECH 2.0 formulations delivered improved performance when compared to both Lexaria s original DehdyraTECH 1.0 and 2.0 concentration-matched formulations, as well as to a medium chain triglyceride ( MCT ) oil based control formulation representative of standard industry practices Summary data is shown below:
Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1
ACCESSWIRE
Up to 2,178% more CBD delivered into bloodstream
Up to 1,737% more CBD delivered into brain tissue
KELOWNA, BC / ACCESSWIRE / May 6, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the Company or Lexaria ), a global innovator in drug delivery platforms, is pleased to announce successful outcomes in its first sets of data from its 2021 applied research and development (R&D) study programs.
Study HYPER-A21-1 included three new DehydraTECH 2.0 formulation variations designed to enable cannabidiol ( CBD ) delivery performance enhancements and pharmacokinetic optimization. All three new DehydraTECH 2.0 formulations delivered improved performance when compared to both Lexaria s original DehdyraTECH 1.0 and 2.0 concentration-matched formulations, as well as to a medium chain triglyceride ( MCT ) oil based control formulation representative of standard industry practices Summa